AliveCor Closes $65 Million Series E Financing: To Accelerate Growth of Its Remote Cardiology Platform For Consumers, Employers, & Providers

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

November 16, 2020

AliveCor today announced their $65 million series E financing led by existing investors OMRON, Khosla Ventures, WP Global Partners, Qualcomm Ventures and Bold Capital Partners.

Proceeds from this financing will be used to accelerate growth of AliveCor’s remote cardiology platform both domestically and around the world. The company’s AI-powered ECG determinations will be augmented with telehealth services, as well as with detection and condition management services for providers and institutions. The enhanced partnership with OMRON will also position the company to include hypertension management within its service portfolio.

To date, AliveCor products have served more than one million customers around the world and recorded more than 85 million ECGs. This vast data set gives the company a meaningful advantage in building new AI-based services to drive a new age of advanced and improved cardiological care. AliveCor believes that comprehensive services coupled with AI-powered diagnostics will have an ongoing impact on cost, quality, and most importantly on responsiveness: resolving false positives and improving response time in medical emergencies.

“We are grateful for the continued confidence of our investors,” said Priya Abani, CEO of AliveCor. “This financing speaks to the transformative power our technology brings to the healthcare system. We remain positioned to fulfill our vision of delivering AI-based, remote cardiological services for the vast majority of cases when cardiac patients are not in front of their doctor.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.